ATE555388T1 - Onkolytische viren zur bestimmung des phänotypus von neoplasmen - Google Patents

Onkolytische viren zur bestimmung des phänotypus von neoplasmen

Info

Publication number
ATE555388T1
ATE555388T1 AT07021569T AT07021569T ATE555388T1 AT E555388 T1 ATE555388 T1 AT E555388T1 AT 07021569 T AT07021569 T AT 07021569T AT 07021569 T AT07021569 T AT 07021569T AT E555388 T1 ATE555388 T1 AT E555388T1
Authority
AT
Austria
Prior art keywords
neoplasms
phenotype
determining
oncolytic viruses
oncolytic
Prior art date
Application number
AT07021569T
Other languages
English (en)
Inventor
Bradley Thompson
Matthew Coffey
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Application granted granted Critical
Publication of ATE555388T1 publication Critical patent/ATE555388T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/14—Reoviridae, e.g. rotavirus, bluetongue virus, Colorado tick fever virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT07021569T 2002-06-28 2003-06-25 Onkolytische viren zur bestimmung des phänotypus von neoplasmen ATE555388T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39203102P 2002-06-28 2002-06-28
US44318803P 2003-01-29 2003-01-29

Publications (1)

Publication Number Publication Date
ATE555388T1 true ATE555388T1 (de) 2012-05-15

Family

ID=30003222

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03737795T ATE377754T1 (de) 2002-06-28 2003-06-25 Onkolytische viren zur bestimmung des phänotypus von neoplasmen
AT07021569T ATE555388T1 (de) 2002-06-28 2003-06-25 Onkolytische viren zur bestimmung des phänotypus von neoplasmen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT03737795T ATE377754T1 (de) 2002-06-28 2003-06-25 Onkolytische viren zur bestimmung des phänotypus von neoplasmen

Country Status (20)

Country Link
US (3) US7306902B2 (de)
EP (2) EP1520175B1 (de)
JP (1) JP2005531306A (de)
CN (1) CN1666105B (de)
AR (1) AR039768A1 (de)
AT (2) ATE377754T1 (de)
AU (2) AU2003245760B2 (de)
BR (1) BR0311983A (de)
CA (1) CA2487824C (de)
DE (1) DE60317331T2 (de)
DK (2) DK1890151T3 (de)
ES (2) ES2385845T3 (de)
HK (2) HK1069877A1 (de)
IL (2) IL165498A0 (de)
MX (1) MXPA04012414A (de)
NZ (1) NZ537116A (de)
PT (1) PT1890151E (de)
SI (1) SI1890151T1 (de)
TW (3) TWI402345B (de)
WO (1) WO2004003562A2 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
US8491884B2 (en) * 2000-05-03 2013-07-23 Oncolytics Biotech Inc. Virus clearance of neoplastic cells from mixed cellular compositions
US7306902B2 (en) * 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
US20040115170A1 (en) * 2001-11-30 2004-06-17 Brown Earl Garnet Oncolytic virus
EP1523333A4 (de) 2002-07-24 2007-01-24 Univ Arizona Verwendung des vaccinia-virus mit deletion des e3l-gens als vakzine-vektor
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
EP1648233A4 (de) * 2003-07-08 2006-08-23 Univ Arizona Mutanten des vaccinia-virus als onkolytika
WO2005111200A1 (en) * 2004-05-17 2005-11-24 Universite De Montreal Novel strains of reoviruses and methods of uses thereof
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
EP1917351A4 (de) 2005-08-01 2009-12-16 Univ Technologies Int Abgeschwächtes reovirus
CA2634591A1 (en) * 2005-12-22 2007-07-05 Memorial Sloan-Kettering Cancer Center Method for detection of cancer cells using virus
US20070190032A1 (en) * 2006-02-13 2007-08-16 Oncolytics Biotech Inc. Use of Local Immune Suppression to Enhance Oncolytic Viral Therapy
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
US9241998B2 (en) * 2007-05-21 2016-01-26 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oncolytic RSV activity
WO2009143468A1 (en) * 2008-05-22 2009-11-26 Uti Limited Partnership Tumor suppressor-based susceptibility of hyperproliferative cells to oncolytic viral therapy
MX339014B (es) * 2008-05-27 2016-05-09 Oncolytics Biotech Inc Modulacion de presion intersticial y suministro y distribucion viral oncolitica.
US8470312B2 (en) * 2008-05-27 2013-06-25 Oncolytics Biotech, Inc. Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
US8481297B2 (en) * 2009-01-08 2013-07-09 Yale University Compositions and methods of use of an oncolytic vesicular stomatitis virus
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
WO2012106281A2 (en) 2011-01-31 2012-08-09 The General Hospital Corporation Multimodal trail molecules and uses in cellular therapies
WO2013052915A2 (en) 2011-10-05 2013-04-11 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic
WO2013138522A2 (en) 2012-03-16 2013-09-19 Genelux Corporation Methods for assessing effectiveness and monitoring oncolytic virus treatment
WO2013158265A1 (en) 2012-04-20 2013-10-24 Genelux Corporation Imaging methods for oncolytic virus therapy
EP2877572B1 (de) 2012-07-24 2018-11-28 The General Hospital Corporation Onkolytische virustherapie für resistente tumoren
US9605074B2 (en) 2012-08-30 2017-03-28 The General Hospital Corporation Multifunctional nanobodies for treating cancer
WO2014055960A1 (en) 2012-10-05 2014-04-10 Genelux Corporation Energy absorbing-based diagnostic and therapeutic methods employing nucleic acid molecules encoding chromophore-producing enzymes
US20160303174A1 (en) * 2013-12-11 2016-10-20 The General Hospital Corporation Stem cell delivered oncolytic herpes simplex virus and methods for treating brain tumors
US10238700B2 (en) 2014-01-02 2019-03-26 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
EA201700181A1 (ru) 2014-10-14 2017-09-29 Галозим, Инк. Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования
CA2977660A1 (en) 2015-02-25 2016-09-15 Memorial Sloan-Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
KR20180006916A (ko) 2015-04-17 2018-01-19 메모리얼 슬로안-케터링 캔서 센터 고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도
MX2018010231A (es) 2016-02-25 2019-06-06 Memorial Sloan Kettering Cancer Center Mva recombinante o mvadele3l que expresa el flt3l humano y uso de los mismos como agentes inmunoterapéuticos contra tumores sólidos.
CA3015650A1 (en) 2016-02-25 2017-08-31 Memorial Sloan Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
CN109715657A (zh) 2016-04-15 2019-05-03 高山免疫科学股份有限公司 Cd80变体免疫调节蛋白及其用途
KR20230051602A (ko) 2016-04-15 2023-04-18 알파인 이뮨 사이언시즈, 인코포레이티드 Icos 리간드 변이체 면역조절 단백질 및 그의 용도
WO2017205674A1 (en) 2016-05-25 2017-11-30 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic vaccinia virus mutants and using same for cancer treatment
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
WO2018022945A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd112 variant immunomodulatory proteins and uses thereof
CA3032120A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
EP3518947B1 (de) * 2016-09-27 2023-07-05 Sator Therapeutics LLC Rekombinante onkolytische viren und verwendungen davon
CN110352245A (zh) 2016-10-20 2019-10-18 高山免疫科学股份有限公司 可分泌变体免疫调节蛋白和工程化细胞疗法
JP2020507349A (ja) 2017-02-09 2020-03-12 インダプタ セラピューティクス インコーポレイテッド 操作されたナチュラルキラー（ｎｋ）細胞ならびにその組成物および方法
CN110809581A (zh) 2017-03-16 2020-02-18 高山免疫科学股份有限公司 Pd-l2变体免疫调节蛋白及其用途
JP2020509776A (ja) 2017-03-16 2020-04-02 アルパイン イミューン サイエンシズ インコーポレイテッド Ｐｄ−ｌ１バリアント免疫調節タンパク質及びその使用
WO2018170026A2 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
CN111107872A (zh) 2017-05-12 2020-05-05 纪念斯隆-凯特林癌症中心 有用于癌症免疫疗法的牛痘病毒突变体
TW201925223A (zh) 2017-10-18 2019-07-01 美商艾爾潘免疫科學有限公司 變異型icos 配位體免疫調節蛋白及相關組合物及方法
ES2966045T3 (es) 2018-06-04 2024-04-18 Calidi Biotherapeutics Inc Vehículos basados en células para la potenciación de la terapia viral
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
US20210363219A1 (en) 2018-06-15 2021-11-25 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
WO2020047161A2 (en) 2018-08-28 2020-03-05 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
CA3116192A1 (en) 2018-11-06 2020-05-14 Calidi Biotherapeutics, Inc. Enhanced systems for cell-mediated oncolytic viral therapy
EP3884041A2 (de) 2018-11-21 2021-09-29 Indapta Therapeutics, Inc. Verfahren zur expansion des subsets von natürlichen killer (nk)-tellen und verwandte zusammensetzungen und verfahren
WO2020113141A2 (en) 2018-11-30 2020-06-04 Alpine Immune Sciences, Inc. Cd86 variant immunomodulatory proteins and uses thereof
JP2022524951A (ja) 2019-02-27 2022-05-11 アクティム・セラピューティクス・インコーポレイテッド 腫瘍、腫瘍常在免疫細胞および腫瘍微小環境にコロニー形成するよう操作した免疫刺激性細菌
CA3180658A1 (en) 2020-04-22 2021-10-28 Indapta Therapeutics, Inc. Natural killer (nk) cell compositions and methods for generating same
WO2022147481A1 (en) 2020-12-30 2022-07-07 Ansun Biopharma Inc. Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
US5670330A (en) * 1992-09-29 1997-09-23 Mcgill University Anti-tumor agent assay using PKR
ATE178490T1 (de) 1993-02-16 1999-04-15 Onyx Pharmaceuticals Cytopathische viren zur therapie und prophylaxe der neoplasie
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
DE69435118D1 (de) 1993-04-30 2008-08-28 Wellstat Biologics Corp Gereinigte Zusammensetzungen von Newcastle-Krankheitvirus
WO1995016464A1 (en) 1993-12-14 1995-06-22 Johns Hopkins University School Of Medicine Controlled release of pharmaceutically active substances for immunotherapy
WO1995032300A1 (en) 1994-05-23 1995-11-30 University Of Medicine & Dentistry Of New Jersey Selective biological destruction of tumor cells
US5585096A (en) 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5840502A (en) 1994-08-31 1998-11-24 Activated Cell Therapy, Inc. Methods for enriching specific cell-types by density gradient centrifugation
US6777177B1 (en) * 1997-10-10 2004-08-17 Vanderbilt University Mammalian genes involved in viral infection and tumor suppression
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
CA2508238C (en) 1997-08-13 2008-01-15 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
CA2305269C (en) 1997-10-09 2012-07-03 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7780962B2 (en) * 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US6475481B2 (en) 1997-11-18 2002-11-05 Canji Inc Purging of stem cell products
EP1061806A4 (de) 1998-03-12 2001-09-12 Univ Pennsylvania Produktive zellen für replikationsselektive viren zur behandlung bösartiger erkrankungen
CA2342203C (en) 1998-08-31 2011-03-01 Julian L. Ambrus Method for removal of hiv and other viruses from blood
EP1390046A4 (de) 1999-04-15 2005-04-20 Wellstat Biologics Corp Behandlung von neoplasmen mit viren
DE19934788B4 (de) * 1999-07-27 2004-05-27 T-Mobile Deutschland Gmbh Verfahren zur automatischen Anpassung von Daten an die Fähigkeiten einer Nutzer-Software
CA2386920C (en) 1999-09-17 2012-01-24 Pro-Virus, Inc. Oncolytic virus
CA2388807C (en) 1999-11-12 2013-08-06 Matthew C. Coffey Viruses for the treatment of cellular proliferative disorders
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AR028040A1 (es) 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de virus de celulas neoplasticas a partir de composiciones celulares mixtas
US7306902B2 (en) * 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
AR028039A1 (es) 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas
CN1250711C (zh) * 2000-06-26 2006-04-12 威尔斯达特生物制剂公司 用病毒清除细胞
WO2002004596A2 (en) 2000-07-07 2002-01-17 President And Fellows Of Harvard College Diagnosing and treating cancer cells using mutant viruses
DE60142485D1 (de) 2000-11-09 2010-08-12 Oncolytics Biotech Inc Verfahren zur Beurteilung von zellulären proliferativen Erkrankungen
US20030138405A1 (en) * 2001-04-17 2003-07-24 Juan Fueyo Conditionally replicative adenovirus to target the Rb and Rb-related pathways

Also Published As

Publication number Publication date
HK1069877A1 (en) 2005-06-03
EP1520175A2 (de) 2005-04-06
AU2008207579A1 (en) 2008-09-18
ES2385845T3 (es) 2012-08-01
AU2003245760A1 (en) 2004-01-19
CA2487824A1 (en) 2004-01-08
SI1890151T1 (sl) 2012-08-31
CN1666105A (zh) 2005-09-07
IL220139A0 (en) 2012-07-31
IL165498A0 (en) 2006-01-15
AU2003245760B2 (en) 2008-07-03
PT1890151E (pt) 2012-05-25
AR039768A1 (es) 2005-03-09
IL220139A (en) 2013-03-24
WO2004003562A2 (en) 2004-01-08
US7306902B2 (en) 2007-12-11
EP1890151B1 (de) 2012-04-25
TW200401032A (en) 2004-01-16
TWI402345B (zh) 2013-07-21
BR0311983A (pt) 2005-04-26
CA2487824C (en) 2013-08-20
HK1112509A1 (en) 2008-09-05
DK1520175T3 (da) 2008-02-11
ATE377754T1 (de) 2007-11-15
TW201005097A (en) 2010-02-01
TWI327167B (en) 2010-07-11
US20100105122A1 (en) 2010-04-29
JP2005531306A (ja) 2005-10-20
AU2008207579B2 (en) 2011-10-20
DK1890151T3 (da) 2012-06-18
US8222036B2 (en) 2012-07-17
NZ537116A (en) 2008-04-30
US20080014577A1 (en) 2008-01-17
CN1666105B (zh) 2015-11-25
EP1520175B1 (de) 2007-11-07
EP1890151A1 (de) 2008-02-20
TWI334444B (en) 2010-12-11
ES2292981T3 (es) 2008-03-16
DE60317331D1 (de) 2007-12-20
WO2004003562A3 (en) 2004-05-06
MXPA04012414A (es) 2005-04-19
US20040029112A1 (en) 2004-02-12
TW200940709A (en) 2009-10-01
DE60317331T2 (de) 2008-08-21

Similar Documents

Publication Publication Date Title
ATE377754T1 (de) Onkolytische viren zur bestimmung des phänotypus von neoplasmen
DK1501921T4 (da) Forbedrede virusrensningsmetoder
NO2012018I1 (no) Canakinumab eller direkte ekvivalenter derav
ATE493986T1 (de) Diarylharnstoffe zur behandlung von pulmonaler hypertonie
ATE357440T1 (de) Benzodiazepin-substituierte piperdine zur verwendung in der behandlung von cardiovaskulären erkrankungen
EP1723238A4 (de) Modifizierte onkolytische viren
DE50212455D1 (de) Verwendung von Dimerdiolen
DE60126814D1 (de) Inhalation von stickoxid
DE60308203D1 (de) Gerät zur bestimmung des stimulationschwellwertes
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE50311465D1 (de) Heisssiegelfähiges Filtermaterial
DE50206735D1 (de) Küchenmaschine zum Zubereiten von Lebensmitteln
ATE480637T1 (de) Methode zur bestimmung der biologischen aktivität von difibrotid
DE602004026773D1 (de) Verfahrensherstellung von ethern
DE60200713D1 (de) Zusammensetzung enthaltend getrocknetes Vollei zur Behandlung von Hepatitis
ATE519860T1 (de) Verwendung von ribozymen zur detektion ebenfalls vorhandener agenzien
DE50302846D1 (de) Gelenkige aufhängung
DE60200296D1 (de) Gerät zur Detektion von Vorsatzlöchern
DE50306263D1 (de) Detektion von toxischen algen
DE602004024640D1 (de) Reinigung von titantetrachlorid
DE60131170D1 (de) Künstliche Lunge des Membrantyps
DE502004010917D1 (de) Rstellung und verwendung
DE60208788D1 (de) Prüfung der arzneistoffempfindlichkeit von viren
DE60123896D1 (de) Vorrichtunng zur Wobbelerfassung
DE60331820D1 (de) Beseitigung von verstopfungen von rohrleitungen